First Fracture Prevention Study In Men Receiving ADT For Prostate Cancer Presented At AACR Annual Meeting

GTx, Inc. (NASDAQ: GTXI) announced that results of the Phase III ADT clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men who have advanced prostate cancer were presented during a late breaking oral session at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

More: continued here

Filed under: Cancer on April 18th, 2008